Fri, August 10, 2018
Thu, August 9, 2018
Wed, August 8, 2018

Robyn Karnauskas Maintained (BMRN) at Strong Buy with Increased Target to $120 on, Aug 9th, 2018

Robyn Karnauskas of Citigroup, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Increased Target from $108 to $120 on, Aug 9th, 2018.

Robyn has made no other calls on BMRN in the last 4 months.



There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $98 on, Monday, August 6th, 2018


These are the ratings of the 6 analyists that currently disagree with Robyn


  • Liana Moussatos of "Wedbush" Maintained at Buy with Increased Target to $120 on, Monday, August 6th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $115 on, Friday, August 3rd, 2018
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Increased Target to $109 on, Friday, August 3rd, 2018
  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $113 on, Tuesday, July 31st, 2018
  • M. Auster of "Credit Suisse" Maintained at Buy with Increased Target to $122 on, Monday, July 9th, 2018
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $133 on, Thursday, May 31st, 2018